Literature DB >> 34750294

Assessment of coronary inflammation in antiretroviral treated people with HIV infection and active HIV/hepatitis C virus co-infection.

Jean Jeudy1, Pratik Patel2, Nivya George3, Shana Burrowes4, Jennifer Husson3,5, Joel Chua3,5, Lora Conn3, Robert G Weiss6, Shashwatee Bagchi3,5.   

Abstract

OBJECTIVE: People with HIV (PWH) and co-infected with hepatitis C virus (PWH + HCV) have increased risk of cardiovascular disease (CVD). Peri-coronary inflammation, measured by fat attenuation index (FAI) on coronary computed tomography angiography (CCTA), independently predicts cardiovascular risk in the general population but has not been studied in the PWH + HCV population. We tested whether peri-coronary inflammation is increased in PWH or PWH + HCV, and whether inflammation changes over time.
DESIGN: Cross-sectional analysis to determine FAI differences among groups. Longitudinal analysis in PWH to assess changes in inflammation over time.
METHODS: Age-matched and sex-matched seropositive groups (PWH and PWH + HCV) virologically suppressed on antiretroviral therapy, HCV viremic, and without prior CVD and matched controls underwent CCTA. Peri-coronary FAI was measured around the proximal right coronary artery (RCA) and left anterior descending artery (LAD). Follow-up CCTA was performed in 22 PWH after 20.6-27.4 months.
RESULTS: A total of 101 participants (48 women) were studied (60 PWH, 19 PWH + HCV and 22 controls). In adjusted analyses, peri-coronary FAI did not differ between seropositive groups and controls. Low attenuation coronary plaque was significantly less common in seropositive groups compared with controls (LAD, P = 0.035; and RCA, P = 0.017, respectively). Peri-coronary FAI values significantly progressed between baseline and follow-up in PWH (RCA: P = 0.001, LAD: P = <0.001).
CONCLUSION: PWH and PWH + HCV without history of CVD do not have significantly worse peri-coronary inflammation, assessed by FAI, compared with matched controls. However, peri-coronary inflammation in mono-infected PWH significantly increased over approximately 22 months. FAI measures may be an important imaging biomarker for tracking asymptomatic CVD progression in PWH.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34750294      PMCID: PMC8795490          DOI: 10.1097/QAD.0000000000003125

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

Review 1.  Role of biomarkers in predicting CVD risk in the setting of HIV infection?

Authors:  Signe W Worm; Priscilla Hsue
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Coronary atherosclerosis characteristics in HIV-infected patients on long-term antiretroviral therapy: insights from coronary computed tomography-angiography.

Authors:  Thomas Senoner; Fabian Barbieri; Agne Adukauskaite; Mario Sarcletti; Fabian Plank; Christoph Beyer; Wolfgang Dichtl; Gudrun M Feuchtner
Journal:  AIDS       Date:  2019-10-01       Impact factor: 4.177

3.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals.

Authors:  Philip Greenland; Laurie LaBree; Stanley P Azen; Terence M Doherty; Robert C Detrano
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

Review 4.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 5.  HIV and coronary heart disease: time for a better understanding.

Authors:  Franck Boccara; Sylvie Lang; Catherine Meuleman; Stephane Ederhy; Murielle Mary-Krause; Dominique Costagliola; Jacqueline Capeau; Ariel Cohen
Journal:  J Am Coll Cardiol       Date:  2013-02-05       Impact factor: 24.094

Review 6.  The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients.

Authors:  Janet Lo; Jorge Plutzky
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

Review 7.  Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.

Authors:  Ahmed Babiker; Jean Jeudy; Seth Kligerman; Miriam Khambaty; Anoop Shah; Shashwatee Bagchi
Journal:  J Clin Transl Hepatol       Date:  2017-08-31

8.  Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.

Authors:  Evangelos K Oikonomou; Mohamed Marwan; Milind Y Desai; Jennifer Mancio; Alaa Alashi; Erika Hutt Centeno; Sheena Thomas; Laura Herdman; Christos P Kotanidis; Katharine E Thomas; Brian P Griffin; Scott D Flamm; Alexios S Antonopoulos; Cheerag Shirodaria; Nikant Sabharwal; John Deanfield; Stefan Neubauer; Jemma C Hopewell; Keith M Channon; Stephan Achenbach; Charalambos Antoniades
Journal:  Lancet       Date:  2018-08-28       Impact factor: 79.321

Review 9.  The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation.

Authors:  Jeremy Yuvaraj; Kevin Cheng; Andrew Lin; Peter J Psaltis; Stephen J Nicholls; Dennis T L Wong
Journal:  Cells       Date:  2021-05-13       Impact factor: 6.600

10.  Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection.

Authors:  Ayten Oguz; Ahmet Engin Atay; Adnan Tas; Gulseren Seven; Mehmet Koruk
Journal:  Gut Liver       Date:  2012-11-13       Impact factor: 4.519

View more
  1 in total

1.  Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review.

Authors:  Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah
Journal:  JAMA       Date:  2022-09-13       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.